Engaging Cooperative Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC)

临床研究有许多不同的形式和规模，一个强大的网络必须适应所有的试验 类型没有一个组织能够单独完成这项工作。我们致力于试验创新和 和CTSA联盟内外的集体网络能力，并有着悠久的历史， 支持这种做法。我们展示了协作创新和共享的卓越能力 支持临床研究协调的工具，包括：全球数据管理，移动的数据收集， 招募、电子健康记录（EHR）研究、单个IRB协调、签约、社区 参与、向参与者回报价值、eConsent、虚拟/远程参与研究和EHR 与REDCap整合。我们将利用和扩大这些计划，因为我们是从事合作 试验加速、信任、创新和能力的网站（狂喜）。我们将建立一个分布式 由6个CTSA协调中心组成的联盟，为TIN增加弹性能力并扩大专业知识 CCC/DCC基础设施。我们的联盟有14名专家试验员，可以为综合方法的使用提供信息 更有效的临床研究。此外，我们将与成熟的生物统计学， 流行病学和研究设计（BERD）小组和健康公平专家，以确保每项研究都有 获得从研究设计到分析所需的专业知识。我们将扩大 能够随时参与全美临床研究的组织，包括历史上的黑人 学院和大学（HBCUs），以达到最需要支持的人口。根据我们的小说改编 结构，合并来自六个不同协调中心的团队，我们的TIC的能力既可扩展， 并与专业知识相匹配，以有意适应所有研究设计类型。由戈登·伯纳德领导， 医学博士，韦斯利自我，医学博士和克里斯托弗林赛，博士，每个经验丰富的领导和合作， 多站点临床试验网络，ECSTATIC将拥抱并利用各种专业知识来构建、测试和共享 新的资源，将加强和加速严格的，可重复的研究，为所有CTSA，以更快地 改善人类健康。我们的具体目标是：1）展示和传播新的综合 更有效的临床研究方法，包括EHR嵌入式，远程无接触和平台 试验，与研究需求保持一致; 2）通过增加潜力，扩大和丰富临床试验能力 参与现场的意向书（EOI）覆盖范围和准备支持（HBCU和基于实践的农村 研究网络），与CTSA更好的流程整合，准备研究团队，以及更广泛的专家 参与; 3）通过创建，评估和传播新方法来创新临床试验方法 用于风险监测、AE报告、直接EHR到REDCap数据采集以及所有CTSA的数据标准;以及 4)提供具有广泛和多样化专业知识的临床和数据协调中心的分布式联盟 提供针对试验设计、人群和条件的支持。

Clinical research comes in many different shapes and sizes, and a robust network must accommodate all trial types. No single organization can do this work alone. We have a deep commitment to both trial innovation and collective network capacity within and beyond the CTSA Consortium and have a lengthy history of supporting this approach. We have demonstrated an exceptional ability to collaboratively innovate and share tools supporting clinical research coordination, including: global data management, mobile data collection, recruitment, Electronic Health Record (EHR) research, single IRB coordination, contracting, community engagement, returning value to participants, eConsent, virtual/remote participation in studies, and EHR integration with REDCap. We will leverage and expand upon these programs as we are Engaging Cooperative Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC). We will establish a distributed alliance of 6 CTSA-aligned coordinating centers to add elastic capacity and broaden expertise to the TIN’s CCC/DCC infrastructure. Our alliance has 14 expert trialists that can inform the use of integrated approaches for more efficient clinical research. Additionally, we will partner with the well-established Biostatistics, Epidemiology, and Research Design (BERD) group and health equity experts to ensure every study has access to needed expertise starting from study design through analysis. We will broaden the types of organizations that can readily participate in clinical research across the U.S., including Historically Black Colleges and Universities (HBCUs), to reach the populations most in need of support. Based on our novel structure, merging teams from six different coordinating center groups, our TIC’s capacity is both scalable and matched by expertise to intentionally accommodate all study design types. Led by Gordon Bernard, MD, Wesley Self, MD, and Christopher Lindsell, PhD, each seasoned in leading and collaborating with multisite clinical trial networks, ECSTATIC will embrace and draw on diverse expertise to build, test, and share new resources that will enhance and accelerate rigorous, reproducible research for all CTSAs, to more rapidly improve human health. Our Specific Aims are to: 1) demonstrate and disseminate novel integrated approaches for more efficient clinical research including EHR-embedded, remote no-touch, and platform trials, aligning with study needs; 2) expand and enrich clinical trial capability by increasing potential participating site Expression of Interest (EOI) reach and readiness support (HBCUs and rural Practice-Based Research Networks), better process integration with CTSAs, preparing study teams, and broader expert engagement; 3) innovate clinical trial methodology by creating, evaluating, and disseminating new methods for risk monitoring, AE reporting, direct EHR to REDCap data capture, and data standards to all CTSAs; and 4) provide a distributed alliance of clinical and data coordinating centers with extensive and diverse expertise to offer support tailored for trial design, population, and condition.